Circulating cf-miRNA as a more appropriate surrogate liquid biopsy marker than cfDNA for ovarian cancer / Aoife Ward Gahlawat, Tania Witte, Peter Sinn & Sarah Schott
Ovarian cancer (OC) is an aggressive disease, primarily diagnosed in late stages with only 20% of patients surviving more than 5 years. Liquid biopsy markers have great potential to improve current diagnostic and prognostic methods. Here, we compared miRNAs and DNA methylation in matched plasma, whole blood and tissues as a surrogate marker for OC. We found that while both cfDNA and cf-miRNAs levels were upregulated in OC compared to patients with benign lesions or healthy controls, only cf-miRNA levels were an independent prognosticator of survival. Following on our previous work, we found members of the miR-200 family, miR-200c and miR-141 to be upregulated in both plasma and matched tissues of OC patients which correlated with adverse clinical features. We could also show that the upregulation of miR-200c and -141 correlated with promoter DNA hypomethylation in tissues, but not in plasma or matched whole blood samples. As cf-miRNAs are more easily obtained and very stable in blood, we conclude that they might serve as a more appropriate surrogate liquid biopsy marker than cfDNA for OC..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
04 April 2023 2023 |
|---|---|
| Erschienen: |
04 April 2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Scientific reports - 13(2023) vom: Apr., Artikel-ID 5503, Seite 1-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gahlawat, Aoife Ward [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Gesehen am 19.06.2023 |
|---|
| Umfang: |
9 |
|---|
| doi: |
10.1038/s41598-023-32243-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1850525889 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | 1850525889 | ||
| 003 | DE-627 | ||
| 005 | 20240328080628.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230619s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-023-32243-x |2 doi | |
| 035 | |a (DE-627)1850525889 | ||
| 035 | |a (DE-599)KXP1850525889 | ||
| 035 | |a (OCoLC)1389528165 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gahlawat, Aoife Ward |e verfasserin |0 (DE-588)1188584294 |0 (DE-627)1667524135 |4 aut | |
| 245 | 1 | 0 | |a Circulating cf-miRNA as a more appropriate surrogate liquid biopsy marker than cfDNA for ovarian cancer |c Aoife Ward Gahlawat, Tania Witte, Peter Sinn & Sarah Schott |
| 264 | 1 | |c 04 April 2023 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.06.2023 | ||
| 520 | |a Ovarian cancer (OC) is an aggressive disease, primarily diagnosed in late stages with only 20% of patients surviving more than 5 years. Liquid biopsy markers have great potential to improve current diagnostic and prognostic methods. Here, we compared miRNAs and DNA methylation in matched plasma, whole blood and tissues as a surrogate marker for OC. We found that while both cfDNA and cf-miRNAs levels were upregulated in OC compared to patients with benign lesions or healthy controls, only cf-miRNA levels were an independent prognosticator of survival. Following on our previous work, we found members of the miR-200 family, miR-200c and miR-141 to be upregulated in both plasma and matched tissues of OC patients which correlated with adverse clinical features. We could also show that the upregulation of miR-200c and -141 correlated with promoter DNA hypomethylation in tissues, but not in plasma or matched whole blood samples. As cf-miRNAs are more easily obtained and very stable in blood, we conclude that they might serve as a more appropriate surrogate liquid biopsy marker than cfDNA for OC. | ||
| 650 | 4 | |a miRNAs | |
| 650 | 4 | |a Molecular medicine | |
| 650 | 4 | |a Ovarian cancer | |
| 700 | 1 | |a Witte, Tania |e verfasserin |0 (DE-588)1069007145 |0 (DE-627)82112496X |0 (DE-576)428348416 |4 aut | |
| 700 | 1 | |a Sinn, Peter |d 1957- |e verfasserin |0 (DE-588)1022590944 |0 (DE-627)717004783 |0 (DE-576)365646342 |4 aut | |
| 700 | 1 | |a Schott, Sarah |d 1981- |e verfasserin |0 (DE-588)133730816 |0 (DE-627)552697281 |0 (DE-576)27460678X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d [London] : Macmillan Publishers Limited, part of Springer Nature, 2011 |g 13(2023) vom: Apr., Artikel-ID 5503, Seite 1-9 |h Online-Ressource |w (DE-627)663366712 |w (DE-600)2615211-3 |w (DE-576)346641179 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g month:04 |g elocationid:5503 |g pages:1-9 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41598-023-32243-x |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41598-023-32243-x |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a ISIL_DE-16 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_381 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a ISIL_DE-LFER | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |c 4 |i 5503 |h 1-9 |g 9 | ||
| 980 | |2 2011 |1 01 |x DE-16 |b 4459213729 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 15-01-24 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 4340405477 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 19-06-23 | ||
| 980 | |2 2403 |1 01 |x DE-LFER |b 4348049300 |c 00 |f --%%-- |d --%%-- |e n |j --%%-- |y l01 |z 04-07-23 | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://doi.org/10.1038/s41598-023-32243-x | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://www.nature.com/articles/s41598-023-32243-x | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2023 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_4 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_9 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1667524240 |a Gahlawat, Aiofe Ward | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_1 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s p |0 (DE-627)1499256965 |a Witte, Tania | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s k |0 (DE-627)1416822720 |a Extern | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |a pos_2 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s p |0 (DE-627)1435647203 |a Sinn, Peter | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s k |0 (DE-627)1416741658 |a Pathologisches Institut | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |a pos_3 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s p |0 (DE-627)1448427479 |a Schott, Sarah | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s k |0 (DE-627)1416740961 |a Universitäts-Frauenklinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |a pos_4 | ||